Description
Introduction:
Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus
Intended Use:
The KRIBIOLISA Insulin Aspart ELISA is used as an analytical tool for quantitative determination of Insulin Aspart in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. In the first step, samples and standards are pipetted into microwells. If Insulin Aspart i s present in samples or standards, it will form complex with Anti-Insulin Aspart antibody, which is pre-coated onto microwells. In the second step, Anti- Insulin Aspart Biotin conjugate is pipetted and incubated. In the third step, HRP Conjugate is pipetted and incubated. Free HRP conjugate will be removed by a washing step. In the fourth step , TM B substrate is added to microwells and color develops proportionally to the amount of Insulin Aspart present in samples or standards. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!